Sutro Biopharma STRO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Financing Component On Unearned Revenue | $911K-22.5% | $759K-31.2% | $646K-49.1% | $832K-52.7% | $1.18M-45.6% | |
| Materials Supply | $1.08M-41.4% | $1.8M+70.2% | $2.44M+2,523% | $5.62M+2,769% | $1.85M+397% | |
| Ongoing Performance Related To Unsatisfied Performance Obligations | $11.96M-7.7% | $6.6M+10.3% | $5.96M+16.9% | $50.43M+183% | $12.96M+79.2% | |
| Research And Development Services | $556K-38.1% | $428K-53.6% | $524K-58.9% | $609K-55.9% | $898K-44.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Sutro Biopharma break its business down?
- Sutro Biopharma (STRO) reports revenue by product across 4 parts — Financing Component On Unearned Revenue, Materials Supply, Ongoing Performance Related To Unsatisfied Performance Obligations and Research And Development Services. Each is extracted from the segment footnotes and tracked over time.
- Where does Sutro Biopharma's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Sutro Biopharma's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
